Advanced Curriculum for Multiple Sclerosis 2021

Advanced Curriculum for
Multiple Sclerosis 2021

The 6th Annual Pre- ACTRIMS 2-Day, CME/CE Course

Date

February 23rd – February 24th, 2021

Location

Interactive, Virtual Program

Overview

The Advanced Curriculum for Multiple Sclerosis 2021 virtual grand rounds experience is an innovative, comprehensive medical education program that delivers clinicians the best in science relative to all aspects of the MS disease spectrum. This two-day, virtual, interactive curriculum experience will utilize a longer-term patient case series to allow for in-depth clinical decision making on MS diagnostics, biomarkers, imaging, accurate differential diagnosis, first-line therapeutic, mitigation of adverse events, specific considerations for limiting disability, reducing progression, monitoring disease activity, switching therapies as needed, treating symptoms, managing special populations, and effectively utilizing the extended healthcare team.

Target Audience

Neurologists, MS specialists, fellows, residents, nurses, pharmacists, and other healthcare professionals involved in the management of patients with multiple sclerosis.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this live material for a maximum of 14.50 AMA PRA Category 1 CreditsTM.

AcademicCME designates this live material for a maximum of 14.50 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 14.50 CPE Contact Hours (1.45 CEUs) of continuing pharmacy education credit (JA4008190-0000-21-001-L04-P).

Financial Support

Supported by educational grants from Biogen; Bristol Myers Squibb Company; EMD Serono; Greenwich Biosciences, a GW Pharmaceuticals PLC Company and Sanofi

Tuesday, February 23rd, 2021
Pre-Registration Digital Self-Assessment Module I 
7:45am – 8:00am EST Welcome, Introduction, and Course Instruction

Course Director – Fred D. Lublin, MD 

MS Diagnostics
8:00am – 9:00am EST Advances in MS Science I

  • Diagnostic Criteria – Joseph R. Berger, MD 
  • Biomarkers – Suhayl Dhib-Jalbut, MD 
  • Imaging – Daniel Reich, MD, PhD
  • Differential Diagnoses – Patricia Coyle, MD 
9:00am – 10:00am EST Case Presentation Series with Interactive Expert Panel – Brenda L. Banwell, MD; Tanuja Chitnis, MD; Andrew Goodman, MD; Jeffrey A. Cohen, MD 
Patient A 17 Y/O F Diagnosed with Optic Neuritis, Abnormal MRI
Patient B 28 Y/O F with Symptoms Consistent with Relapsing-Remitting MS
Patient C 40 Y/O M with 10-Year History of Multiple Neurological Symptoms
Patient D 52 Y/O F with a 15-Year History of MS, Disease Actively Progressing 
Patient E 65 Y/O M with Gradual Worsening Gait (never had a relapse)
Therapeutic Decision Making
10:00am – 12:00pm EST Advances in MS Science II

  • S1P – Mark S. Freedman, MD
  • B Cell Inhibitors – Anne Cross, MD
  • T Cell Inhibitors – Peter Calabresi, MD
  • BTK – Benjamin Segal, MD 
  • Faculty Panel Discussion
12:00pm – 1:00pm EST Case Presentation Series with Interactive Expert Panel – Faculty: Brenda L. Banwell, MD; Tanuja Chitnis, MD; Andrew Goodman, MD; Jeffrey A. Cohen, MD
Patient A 17 Y/O F Diagnosed with MS, Initiating First-Line Therapy
Patient B 28 Y/O F Symptom Free on Treatment Now Pregnant
Patient C 40 Y/O M NMO, Considerations for Initiating Therapy
Patient D 52 Y/O F Advanced Therapeutic Decision-Making 
Patient E 65 Y/O M Non-Ambulatory, Urinary Incontinence
1:00pm – 2:00 pm  EST

2:00pm – 3:00pm EST 

The New and Emerging Role of Bruton’s Tyrosine Kinase Inhibitor (BTKi) Therapeutics to Improve Long-Term Outcomes in Patients with Relapsing Multiple Sclerosis 

Benjamin M. Greenberg, MD; Aaron Miller, MD; Anthony Traboulsee, MD

*Supported by an independent educational grant from EMD Serono

A Scientific Analysis: The Long-Term Role for S1P Receptor (1,5) Modulator Therapeutics for the Effective Management of Patients with Relapsing MS

Mark S. Freedman, MD; Ilana Katz-Sand, MD; Clyde Markowitz, MD

*Supported by an independent educational grant from Bristol Myers Squibb Company

 

Wednesday, February 24th, 2021
Optimizing Outcomes for MS Patients
8:00am – 9:30am EST Advances in MS Science III

  • Best Practices for Family Planning –Patricia Coyle, MD
  • Sleep Health and the MS Patient – James Sumowski, MD
  • Advances in Specialized Rehabilitation for MS– Francois Bethoux, MD 
  • The Pharmacists Role in MS Therapeutics – John Fanikos, RPh 
  • Updated Strategies for Patient Education and Shared Decision-Making – Amy Perrin Ross, APN, MSN, CNRN, MSCN 
  • COVID-19 Comorbidity and the MS Patient –Joseph Berger, MD
Comprehensive MS Patient Care
9:30am – 11:00am EST Advances in MS Science IV

  • Risk Mitigation – Stephen Krieger, MD 
  • Slow Progression – Peter Calabresi, MD
  • Preserve Cognition – Clyde Markowitz, MD 
  • Maintain Brain Volume – Daniel Reich, MD, PhD
  • Remyelination – Jack Antel, MD
11:00am – 12:00pm EST Case Presentation Series with Interactive Expert Panel – Brenda L. Banwell, MD; Tanuja Chitnis, MD; Andrew Goodman, MD; Jeffrey A. Cohen, MD
Patient A 17 Y/O F Relapse Free, Struggling in School, Reporting Emotional Distress
Patient B 28 Y/O F 3 Years Postpartum New Onset of Symptoms
Patient C 40 Y/O M Appears Stable, Assess Disease Progression
Patient D 52 Y/O F Continuing to Progress? Switch Therapies 
Patient E 65 Y/O M Unchanged Symptoms Now with Poor Cognition
  What Can We Do Better Moving Forward?
12:00pm – 1:00pm EST Advances in MS Science V – Gary Cutter, MS, PhD; Anne Cross, MD

  • The Need to Update Clinical Trial Design 
  • The New Primary and Secondary Endpoints
  • Faculty Panel Discussion
1:00pm – 2:00pm EST

2:00pm – 3:00pm EST

Applying New Science to Symptom Management Across the Spectrum of Multiple Sclerosis

Francois Bethoux MD; Stephen Krieger, MD; Amy Perrin Ross, APN, MSN, CNRN, MSCN

*Supported by an independent educational grant from Greenwich Biosciences, a GW Pharmaceuticals PLC Company

Applying New Science to Patient-Focused Treatment Strategies Across the Spectrum of Multiple Sclerosis                                      

Patricia Coyle, MD; June Halper, MSN, APN-C, MSCN; Clyde Markowitz, MD

*Supported by an independent educational grant from Biogen

Americans with Disabilities Act

Event Staff will be glad to assist you with any questions or special needs. Please contact AcademicCME at [email protected] or 610-687-3300.

 

Further details regarding how to join the virtual sessions will be emailed to the address used to register prior to the event. Feel free to also follow us on Twitter @academiccme for real-time updates and information.

_____________________________________________________

This activity is being held in conjunction with the ACTRIMS Forum 2021, brought to you virtually from Thursday, February 25th to Saturday, February 27th, 2021. For more information and to register for the forum, please visit: https://forum.actrims.org/